Cargando…

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

Detalles Bibliográficos
Autores principales:	Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506560/ http://dx.doi.org/10.1016/j.annonc.2020.08.114

Ejemplares similares

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2022)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
por: Borghetti, Paolo, et al.
Publicado: (2022)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

1241. Surveillance for Viral Respiratory Infections in Pediatric Chronic Care Facilities
por: Prill, Mila M, et al.
Publicado: (2018)

Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2023)

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
por: Denault, Marie-Hélène, et al.
Publicado: (2023)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, W., et al.
Publicado: (2020)

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
por: Ghebeh, Hazem, et al.
Publicado: (2021)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
por: Kazda, Christof M., et al.
Publicado: (2017)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

CB2 Agonist (AM1241) Improving Effect on Ovalbumin-Induced Asthma in Rats
por: Parlar, Ali, et al.
Publicado: (2020)

Pretreatment with AM1241 Enhances the Analgesic Effect of Intrathecally Administrated Mesenchymal Stem Cells
por: Xie, Junran, et al.
Publicado: (2019)

Brain Awareness Week and Beyond: Encouraging the Next Generation
por: McNerney, Colleen D., et al.
Publicado: (2009)

Can MIS-C develop beyond 16 weeks?
por: Ekemen Keleş, Yıldız, et al.
Publicado: (2021)

Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off
por: Li, Jin, et al.
Publicado: (2017)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
por: Joshi, Monika, et al.
Publicado: (2023)

In silico characterization of the motor subunit of the e.coli. restriction-modification system EcoR1241
por: Sinha, Dhiraj, et al.
Publicado: (2013)

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
por: Michael, M, et al.
Publicado: (2005)

A Randomised Trial of an Eight-Week, Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan
por: Leslie, Toby, et al.
Publicado: (2008)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer
por: Zhang, Qi, et al.
Publicado: (2017)

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
por: Wang, Kailin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i0ft16sudvs4jmp4bsdq2b06ld